XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

						For the Three Months Ended September 30, 2024
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Revenues:
Rental income						$	52,901					$	—					$	8,734					$	61,635
Residents fees and services						—						312,005						—						312,005
Total revenues						52,901						312,005						8,734						373,640
Expenses:
Property operating expenses						25,074						284,572						51						309,697
Depreciation and amortization						18,773						47,343						2,843						68,959
General and administrative						—						—						13,933						13,933
Acquisition and certain other transaction related costs						—						—						331						331
Impairment of assets						23,031						—						—						23,031
Total expenses						66,878						331,915						17,158						415,951
Gain on sale of properties						111						—						—						111
Interest and other income						—						—						2,575						2,575
Interest expense						(2,319)						(54)						(57,070)						(59,443)
Loss before income tax expense and equity in net earnings (losses) of investees						(16,185)						(19,964)						(62,919)						(99,068)
Income tax expense						—						—						(148)						(148)
Equity in net earnings (losses) of investees						1,707						—						(1,180)						527
Net loss						$	(14,478)					$	(19,964)					$	(64,247)					$	(98,689)

						For the Nine Months Ended September 30, 2024
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Revenues:
Rental income						$	161,605					$	—					$	25,550					$	187,155
Residents fees and services						—						928,653						—						928,653
Total revenues						161,605						928,653						25,550						1,115,808
Expenses:
Property operating expenses						73,253						847,526						587						921,366
Depreciation and amortization						58,488						141,176						7,785						207,449
General and administrative						—						—						27,763						27,763
Acquisition and certain other transaction related costs						—						—						2,243						2,243
Impairment of assets						41,718						—						—						41,718
Total expenses						173,459						988,702						38,378						1,200,539
Loss on sale of properties						(18,976)						—						—						(18,976)
Interest and other income						—						—						7,215						7,215
Interest expense						(3,435)						(183)						(172,103)						(175,721)
Loss on modification or early extinguishment of debt						—						—						(209)						(209)
Loss before income tax expense and equity in net (losses) earnings of investees						(34,265)						(60,232)						(177,925)						(272,422)
Income tax expense						—						—						(505)						(505)
Equity in net (losses) earnings of investees						(18,173)						—						8,291						(9,882)
Net loss						$	(52,438)					$	(60,232)					$	(170,139)					$	(282,809)

						As of September 30, 2024
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Total assets						$	1,726,082					$	3,111,775					$	447,339					$	5,285,196

						For the Three Months Ended September 30, 2023
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Revenues:
Rental income						$	55,058					$	—					$	8,332					$	63,390
Residents fees and services						—						293,134						—						293,134
Total revenues						55,058						293,134						8,332						356,524
Expenses:
Property operating expenses						25,784						272,445						203						298,432
Depreciation and amortization						20,175						44,587						2,474						67,236
General and administrative						—						—						6,954						6,954
Acquisition and certain other transaction related costs						—						—						3,676						3,676
Impairment of assets						427						729						—						1,156
Total expenses						46,386						317,761						13,307						377,454
Interest and other income						—						115						3,128						3,243
Interest expense						(119)						(79)						(47,560)						(47,758)
Income (loss) before income tax expense and equity in net losses of investees						8,553						(24,591)						(49,407)						(65,445)
Income tax expense						—						—						(189)						(189)
Equity in net losses of investees						(145)						—						—						(145)
Net income (loss)						$	8,408					$	(24,591)					$	(49,596)					$	(65,779)

						For the Nine Months Ended September 30, 2023
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Revenues:
Rental income						$	165,448					$	—					$	25,753					$	191,201
Residents fees and services						—						857,572						—						857,572
Total revenues						165,448						857,572						25,753						1,048,773
Expenses:
Property operating expenses						73,237						796,733						770						870,740
Depreciation and amortization						63,065						129,891						7,474						200,430
General and administrative						—						—						20,111						20,111
Acquisition and certain other transaction related costs						—						—						9,812						9,812
Impairment of assets						14,034						4,346						—						18,380
Total expenses						150,336						930,970						38,167						1,119,473
Gain on sale of properties						—						1,233						—						1,233
Gains on equity securities, net						—						—						8,126						8,126
Interest and other income						—						1,581						10,991						12,572
Interest expense						(344)						(502)						(142,076)						(142,922)
Loss on modification or early extinguishment of debt						—						—						(1,075)						(1,075)
Income (loss) before income tax expense and equity in net earnings of investees						14,768						(71,086)						(136,448)						(192,766)
Income tax expense						—						—						(379)						(379)
Equity in net earnings of investees						2,137						—						—						2,137
Net income (loss)						$	16,905					$	(71,086)					$	(136,827)					$	(191,008)

			As of December 31, 2023
			Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Total assets			$	1,866,422					$	3,134,978					$	444,736					$	5,446,136

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration